Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.

Cella, David; Cappelleri, Joseph C; Bushmakin, Andrew; Charbonneau, Claudie; Li, Jim Z; Kim, Sindy T; Chen, Isan; Michaelson, M Dror; Motzer, Robert J

Cella, David; Cappelleri, Joseph C; Bushmakin, Andrew; Charbonneau, Claudie; Li, Jim Z; Kim, Sindy T; Chen, Isan; Michaelson, M Dror; Motzer, Robert J.

Afiliação

Cella D; Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, IL; Pfizer Global Research and Development, Groton, CT, La Jolla, CA, and New York; Memorial Sloan-Kettering Cancer Center, New York, NY; and Massachusetts General Hospital Cancer Center, Boston, MA.

J Oncol Pract ; 5(2): 66-70, 2009 Mar.

Article em En | MEDLINE | ID: mdl-20856722

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2009 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2009 Tipo de documento: Article